Squarepoint
BOLT icon

Squarepoint’s Bolt Biotherapeutics BOLT Stock Holding History

Squarepoint’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,836
Closed -$78.9K – 4296
2025
Q3 		$78.9K Buy
14,836
+2,448
+20% +$13.6K ﹤0.01% 4156
2025
Q2 		$72.2K Buy
12,388
+8,193
+195% +$54.2K ﹤0.01% 4248
2025
Q1 		$33.6K Buy
4,195
+1,746
+71% +$16.8K ﹤0.01% 4399
2024
Q4 		$26.2K Buy
+2,449
New +$29.6K ﹤0.01% 4919
2024
Q2 		– Sell
-3,901
Closed -$109K – 4077
2024
Q1 		$109K Sell
3,901
-88
-2% -$2.04K ﹤0.01% 3785
2023
Q4 		$89.3K Sell
3,989
-13
-0.3% -$253 ﹤0.01% 3771
2023
Q3 		$83.2K Buy
4,002
+801
+25% +$19.6K ﹤0.01% 3588
2023
Q2 		$81.9K Buy
+3,201
New +$102K ﹤0.01% 3393
2022
Q1 		– Sell
-707
Closed -$69K – 2850
2021
Q4 		$69K Buy
+707
New +$134K ﹤0.01% 2988

Other funds holding BOLT

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TC
T3 Companies New York $76.8M AUM
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint's BOLT Position: Q4 2025 in Review

Squarepoint sold out of Bolt Biotherapeutics (BOLT) in Q4 2025, closing a stake of 14,836 shares — an estimated $78.9K sold.

Squarepoint first reported a position in BOLT in Q4 2021 and held it in 9 quarters. The position peaked at $109K in Q1 2024. 21 funds tracked by Wall St. Rank hold BOLT as of Q4 2025.

  • Squarepoint reported no remaining Bolt Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Squarepoint sold 14,836 Bolt Biotherapeutics shares in Q4 2025, an estimated $78.9K.
  • Squarepoint first reported a position in Bolt Biotherapeutics in Q4 2021 and held it in 9 quarters.
  • Squarepoint's Bolt Biotherapeutics position peaked at $109K in Q1 2024.
  • 21 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q4 2025.

Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.